CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) Files An 8-K Results of Operations and Financial Condition

CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item2.02 Results of Operations and Financial Condition.

On March 31, 2017, CASI Pharmaceuticals, Inc. (the Company)
issued a press release reporting its financial results for the
three month period and fiscal year ending December 31, 2016. The
press release is furnished as Exhibit99.1 to this Current Report
on Form 8-K.

The information on this Current Report on Form 8-K (including
Exhibit99.1) shall not be deemed filed for purposes of Section18
of the Securities Act of 1934, as amended (the Exchange Act) or
otherwise subject to the liabilities of that Section, nor shall
it be deemed incorporated by reference in any filing by the
Company under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits
99.1 Press Release of CASI Pharmaceuticals, Inc., dated March 31,


CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).


CASI PHARMACEUTICALS, INC. (NASDAQ:CASI) closed its last trading session down -0.02 at 1.35 with 10,958 shares trading hands.

An ad to help with our costs